BackImmunogen Overview

Immunogen Receivables

Track Immunogen's receivables ($130M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$130.69M
↑ 3018.44% YoYΔ $126.50M vs prior year quarter

Peer average / median

Loading

Immunogen Receivables History

Loading

Immunogen vs. peers: Receivables Comparison

Loading

Immunogen Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Immunogen (IMGN) FAQ

As of the most recent data (September 2023), IMGN shows a receivables of $130M. That compares with $4.2M in the prior-year period — up 3018.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IMGN's receivables is now $130M (was $4.2M) — a 3018.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Immunogen is outperforming or lagging.

Tracking IMGN's receivables over time shows whether Immunogen is scaling, shrinking, or reshaping that part of the business. The current reading is $130M That compares with $4.2M in the prior-year period — up 3018.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Immunogen's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $130M) with ownership activity and broader fundamentals.

Immunogen's receivables is $130M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.